检索结果-南通市图书馆

Soluble CD163 and CD163 Expression on Monocytes Associated with Chronic Hepatitis B Inflammation and hbsag loss

Journal of Clinical and Translational Hepatology 2022年第6期10卷 1059-1067页

作者： Peilin Xie Bilian Yao Dao Huang Yongyan Chen Qiming Gong Xinxin Zhang Department of Infectious Diseases Research Laboratory of Clinical VirologyRuijin HospitalShanghai Jiao Tong Univer-sity School of MedicineShanghaiChina Department of General Practice Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina Department of Geriatrics Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina Department of Infectious Diseases Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina

Background and Aims:Monocyte/macrophage-associat-ed CD163 is an indicator of the severity of liver inflam-mation and cirrhosis,but the difference of soluble CD163(sCD163)levels in chronic hepatitis B(CHB)patients and hepatitis B surface antigen(hbsag)-loss patients is ***,we aimed to compare the sCD163 levels in CHB patients and hbsag-loss patients with or without an-tiviral ***:sCD163 and CD163 expres-sion on monocytes were compared among four groups,healthy subjects,treatment-naïve CHB patients,sponta-neous hbsag-loss patients,and treatment-related hbsag-loss *** correlation between sCD163 levels and clinical parameters in CHB patients was analyzed.A group of 80 patients with hepatitis B virus(HBV)infection and liver biopsy were ***:sCD163 levels were higher in the CHB group than in the other three ***163 levels were higher in treatment-related hbsag-loss patients than in spontaneous hbsag-loss ***163 levels were negatively correlated with hepatitis B e-antigen(HBeAg)and hbsag levels in HBeAg-positive ***-er biopsy results further demonstrated that sCD163 levels were elevated in CHB patients with substantial inflamma-tion(A≥2)or fibrosis(F≥2).The sCD163 model was more sensitive in predicting inflammation than other noninvasive *** levels were higher in patients with normal ala-nine aminotransferase levels and significant inflammation(A≥2)than in patients with no or mild ***-clusions:sCD163 and CD163 expression on monocytes were associated with CHB inflammation and hbsag loss,and may be used as markers to predict HBV-specific im-mune activation.

关键词： CD163 Hepatitis B virus hbsag loss Monocytes Immune activa-tion

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Early Serum hbsag Kinetics as Predictor of hbsag loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a

引用

Virologica Sinica 2021年第2期36卷 311-320页

作者： Minghui Li Lu Zhang Yao Lu Qiqi Chen Huihui Lu Fangfang Sun Zhan Zeng Gang Wan Linqing Zhao Yao Xie Department of Hepatology Division 2 Beijing Ditan HospitalCapital Medical UniversityBeijing 100015China Department of Hepatology Division 2 Peking University Ditan Teaching HospitalBeijing 100015China Department of Biostatistics Beijing Ditan HospitalCapital Medical UniversityBeijing 100015China Laboratory of Virology Capital Institute of Pediatrics Beijing 100020China

Hepatitis B surface antigen(hbsag)loss is an ideal treatment endpoint for patients with chronic hepatitis B(CHB).We investigated the predictive value of on-treatment hbsag levels for hbsag loss in hepatitis B e antigen(HBe Ag)-negative CHB patients who received 120-week PEG-IFNα-2a *** HBV DNA,hbsag,and anti-HBs levels were assayed at baseline and every 3 months during the *** 81 patients,12 achieved hbsag loss,20 achieved hbsag\100 IU/mL,and 49 maintained HBs Ag C 100 IU/*** loss rate was only 3.7%at 48 weeks,while it reached to 11.1%and 14.8%after treatment of 96 weeks and 120 *** cutoff HBs Ag levels at 12 weeks predicting hbsag loss at 96 weeks and 120 weeks of treatment were 400 IU/mL and 750 IU/mL,with AUC 0.725 and 0.722,positive predictive value(PPV)29.41%and 30.56%,and negative predictive value(NPV)93.75%and 97.78%,*** cutoff hbsag levels at 24 weeks predicting hbsag loss at 96 weeks and 120 weeks of treatment were 174 IU/m L and 236 IU/mL respectively,with AUC 0.925 and 0.922,PPV 40.0%and 46.15%,and both NPV 100%.The predictive ability of the cutoff hbsag levels at 24 weeks was better than that at 12 weeks for HBs Ag loss at either 96 or 120 weeks(χ~2=3.880,P=0.049 andχ~2=4.412,P=0.036).These results indicate that extended therapy is critical to hbsag loss in HBe Ag-negative CHB patients during PEG-IFN treatment,and the hbsag level at 24 weeks can be used to predict hbsag loss during tailoring PEG-IFN therapy.

关键词： Chronic hepatitis B(CHB) Hepatitis B surface antigen(hbsag) Pegylated interferon hbsag loss HBeAg negative

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

hbsag loss Due to Tenofovir Treatment for HBV Reactivation Following DAAs Therapy in One Patient with HBV-HCV Coinfection

引用

Infectious Diseases & Immunity 2021年第2期1卷 115-118页

作者： Dan-Dan He Wei-Zhe Li Shuo Huang Li-Ping Zhang Jing-Jing Li Zhao-Hai Zeng Zu-Jiang Yu Qing-Lei Zeng The Department of Infectious Diseases Guangshan County People’s HospitalXinyang CityHenan 465450China Department of Infectious Diseases and Hepatology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenan 450052China Clinical Laboratory Department of Infectious Diseases and HepatologyThe First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenan 450052China

Hepatitis B virus(HBV)reactivation induced by administration of direct-acting antiviral agents(DAAs)to treat hepatitis C virus(HCV)infection has been reported in previous studies,the subsequent clinical outcomes varied from no symptom to liver failure or death,however,the timing of anti-HBV treatment is *** report the clinical HBV reactivation in a 51 years old female fibrotic patient with chronic HBV-HCV infection during the paritaprevir/ritonavir/ombitasvir and dasabuvir(PrOD)*** baseline HCV RNA,HBV DNA,alanine aminotransferase(ALT),and liver stiffness measurement levels were 5,560,000IU/mL,loss occurred at 80weeks of anti-HBV *** study may extend our understanding of the timing of anti-HBV therapy to prevent potential HBV reactivation during DAAs treatment in HBVHCV coinfected patients,and proper initiation timing may lead to functional cure of chronic HBV infection.

关键词： Coinfection DAAs hbsag loss Hepatitis B virus Hepatitis C virus Reactivation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Consolidation treatment needed for sustained hbsag-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients

引用

Virologica Sinica 2022年第3期37卷 390-397页

作者： Minghui Li Fangfang Sun Xiaoyue Bi Yanjie Lin Liu Yang Yao Lu Lu Zhang Gang Wan Wei Yi Linqing Zhao Yao Xie Department of Hepatology Division 2 Beijing Ditan HospitalCapital Medical UniversityBeijing100015China Department of Hepatology Division 2 Peking University Ditan Teaching HospitalBeijing100015China Department of Biostatistics Beijing Ditan HospitalCapital Medical UniversityBeijing100015China Department of Gynecology and Obstetrics Beijing Ditan HospitalCapital Medical UniversityBeijing100015China Laboratory of Virology Beijing Key Laboratory of Etiology of Viral Diseases in ChildrenCapital Institute of PediatricsBeijing100020China

Hepatitis B surface antigen(hbsag)clearance is considered as functional cure in patients with chronic hepatitis B(CHB).This study aimed to assess the durability of hbsag clearance achieved by interferon-based therapies in patients with CHB who were originally positive for hepatitis B envelope antigen(HBeAg).In this prospective study,HBeAg-positive CHB patients with confirmed hbsag loss under interferon-based therapies were enrolled within 12 weeks from end of treatment and followed up for 48 *** markers,biochemical indicators,and liver imaging examinations were observed every 3–6 *** functional cure was analysed as primary *** associated with sustained hbsag loss or reversion was also *** rate of hbsag loss sustainability was 91.8%(212/231).Patients receiving consolidation treatment for 12–24weeks or≥24 weeks had higher rates of sustained hbsag negativity than those receiving consolidation treatment forhbsag reversion and HBV DNA reversion was 8.2%and 3.9%,*** treatment of≥12 weeks[odd ratio(OR)3.318,95%confidence interval(CI)1.077–10.224,P=0.037)was a predictor of sustained functional cure,and HBeAg-positivity at cessation of treatment(OR 12.271,95%CI 1.076–139.919,P=0.043)was a predictor of hbsag ***-alpha induced functional cure was durable and a consolidation treatment of≥12–24 weeks was needed after hbsag loss in HBeAg-positive CHB patients.

关键词： Chronic hepatitis B(CHB) Functional cure HBeAg positive hbsag loss Interferon(IFN)

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Immunomodulatory and Antiviral Therapy Improved Functional Cure Rate in CHB Patients with High hbsag Level Experienced NA

引用

Journal of Clinical and Translational Hepatology 2023年第5期11卷 1003-1010页

作者： Hongyu Jia Guodong Yu Jiong Yu Xiaoli Zhang Lisha Yang Bin Wang Jiming Zhang Lang Bai Xinxin Zhang Kai Wang Ping Zhao Dongliang Yang Yingren Zhao Yanyan Yu Yimin Zhang Jueqing Gu Chanyuan Ye Huan Cai Yingfeng Lu Dairong Xiang Liang Yu Jiangshan Lian Jianhua Hu Shanyan Zhang Ciliang Jin Yida Yang State Key Laboratory for Diagnosis and Treatment of Infectious Diseases National Clinical Research Center for Infectious DiseasesNational Medical Center for Infectious DiseasesCollaborative Innovation Center for Diagnosis and Treatment of Infectious DiseasesThe First Affiliated HospitalZhejiang University School of MedicineResearch Units of Infectious disease and MicroecologyChinese Academy of Medical SciencesHangzhouZhejiangChina Department of Infectious Diseases Branch of the First Affiliated Hospital of Zhejiang University School of MedicineNingboZhejiangChina Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS) Shanghai Institute of Infectious Disease and BiosecurityShanghaiChina Department of Infectious Diseases Huashan HospitalFudan UniversityShanghaiChina Center of Infectious Diseases West China Hospital of Sichuan UniversityChengduSichuanChina Department of Infectious Disease Research Laboratory of Clinical VirologyRuijin HospitalShanghai Jiao Tong UniversitySchool of MedicineShanghaiChina Department of Hepatology Qilu Hospital of Shandong UniversityJinanShandongChina International Center for Liver Disease Treatment 302 Hospital BeijingBeijingChina Department of Infectious Diseases Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubeiChina Department of Infectious Diseases The First Affiliated Hospital of Xi’an Jiaotong UniversityXi’anShaanxiChina Department of Infectious Diseases Peking University First HospitalBeijingChina

Background and Aims:A functional cure,or hepatitis B virus(HBV)surface antigen(hbsag)loss,is difficult to achieve in patients with hepatitis B virus e antigen(HBeAg)-positive chronic hepatitis *** HBV vaccine and granulocyte-macrophage colony-stimulating factor(GM-CSF)have been reported to help reduce hbsag levels and promote hbsag *** this prospective randomized trial,we evaluated hbsag loss in patients receiving pegylated interferon α2b(PEGIFN-α2b)and tenofovir disoproxil fumarate(TDF),with and without GM-CSF and HBV ***:A total of 287 patients with HBeAg positive chronic hepati-tis B and seroconversion after nucleot(s)ide analog treat-ment were assigned randomly to three treatment groups for 48 weeks,TDF alone(control),PEGIFN-α2b+TDF,and PEGIFN-α2b+TDF+GM-CSF+HBV *** prima-ry endpoints were the proportions of patients with hbsag loss and seroconversion at 48 and 72 ***/ts:The cumulative hbsag loss rates in the control,PEGIFN-α2b+TDF,and PEGIFN-α2b+TDF+GM-CSF+HBV vaccine groups at week 48 were 0.0%,28.3%,and 41.1%,*** cumulative hbsag seroconversion rates in these groups at week 48 were 0.0%,21.7%,and 33.9%,*** regression analysis showed that GM-CSF use plus HBV vaccination was significantly associated with hbsag loss(p=0.017)and seroconversion(p=0.030).Con-clusions:In patients with HBeAg-positive chronic hepatitis B and seroconversion after nucleot(s)ide analog treatment,immunomodulatory/antiviral treatment regimens effective-ly improved hbsag loss,and the regimen including GM-CSF and HBV vaccination was most effective.

关键词： Chronic hepatitis B hbsag loss Functional cure Immunomodulatory/antiviral therapy Pegylated interferon-α2b Tenofovir disoproxil fumarate Granulacyte-macrophage colony-stimulating factor Hepatitis B virus vaccine

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：